Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Efavirenz
Drug: Bupropion
Drug: Rosuvastatin
Drug: Montelukast

First Posted Date: 2015-03-27

Last Posted Date: 2017-10-11

Lead Sponsor: Indiana University

Target Recruit Count: 70

Registration Number: NCT02401256

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

Sleep and Cognition After Atripla to Stribild Switch

Phase 4

Conditions: HIV

Interventions: Drug: Stribild
Drug: Atripla

First Posted Date: 2014-11-05

Last Posted Date: 2016-03-14

Lead Sponsor: University of Hawaii

Target Recruit Count: 30

Registration Number: NCT02283060

Locations: 🇺🇸
Hawaii Center for AIDS, Honolulu, Hawaii, United States

A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation

Completed

Conditions: HIV
Pregnancy
Breastfeeding

Interventions: Drug: Nevirapine
Drug: Efavirenz

First Posted Date: 2014-10-21

Last Posted Date: 2017-09-06

Lead Sponsor: Adeniyi Olagunju

Target Recruit Count: 460

Registration Number: NCT02269462

Locations: 🇳🇬
St Monica's Hospital, Adikpo, Benue State, Nigeria
🇳🇬
Bishop Murray Medical Centre, Makurdi, Benue State, Nigeria
🇳🇬
St Mary's Hospital, Okpoga, Benue State, Nigeria

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Drug: TVD
Drug: ATR
Drug: STB
Drug: RTV
Drug: ATV
Drug: ABC/3TC
Drug: Iohexol

First Posted Date: 2014-09-23

Last Posted Date: 2018-01-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 72

Registration Number: NCT02246998

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Efavirenz

First Posted Date: 2014-08-27

Last Posted Date: 2014-08-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02226991

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Drug: Moxifloxacin
Drug: Placebo
Drug: Efavirenz

First Posted Date: 2014-06-17

Last Posted Date: 2015-09-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02164812

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Efavirenz
Drug: Raltegravir

First Posted Date: 2013-11-21

Last Posted Date: 2019-02-25

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 107

Registration Number: NCT01989910

Locations: 🇨🇳
Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei, Taiwan

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

Phase 4

Terminated

Conditions: Drug Interaction

Interventions: Drug: Efavirenz

First Posted Date: 2013-11-08

Last Posted Date: 2018-05-11

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT01980342

Locations: 🇺🇸
Johns Hopkins University Bayview Medical Center, Baltimore, Maryland, United States

LAAM-HAART PET Imaging

Early Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Radiation: [11c] LAAM
Drug: Ritonavir
Drug: Efavirenz

First Posted Date: 2013-09-05

Last Posted Date: 2017-12-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT01935830

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

Phase 4

Completed

Conditions: HCV Coinfection
HIV Infection

Interventions: Drug: Raltegravir
Drug: Efavirenz

First Posted Date: 2013-07-16

Last Posted Date: 2017-07-25

Lead Sponsor: Juan Macías

Target Recruit Count: 45

Registration Number: NCT01900015

Locations: 🇪🇸
H.U. Valme, Seville, Spain
🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸
Hospital La Línea, La Línea de la Concepción, Cádiz, Spain

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy